BioSpace News Archive

The retirement will be effective after the topline data release from the ongoing MEDALIST and BELIEVE Phase 3 clinical trials with luspatercept, expected to occur in the middle of this year.

NeuroRx is developing a sequential treatment regimen of NRX-100 and NRX-101, and will begin enrolling patients shortly in a Phase 2b/3 pivotal study targeting severe bipolar depression in patients with ASIB.

The funds will be used to expand its growing pipeline and progress several early stage molecules towards the clinic.

Mr. Epstein is an Executive Partner at Flagship Pioneering.

The Agreement also creates a on-going technology partnership between the two companies for future advancements that can be used for the world-wide audiological and hearing aid industry.

Menopause has published their proof-of-concept study evaluating the efficacy of Fiera, a women’s personal care device developed to enhance libido in both premenopausal and postmenopausal women.

resTORbio announced that Lynne Sullivan, Senior Vice President of Finance for Biogen, Inc. has joined the resTORbio board of directors as an independent director.

The new 7600 square feet custom-built, state-of-the-art facility hosts Denovo’s biomarker discovery platform, US clinical team and serves as Denovo’s US headquarters.

The technology will enable new products for a leading segment of RB’s product portfolio. Detailed financial terms were not disclosed.

The newly formed board will be chaired by the former CEO of the ASCO, Dr. Allen Lichter, who is joined by Dr. Shaomeng Wang, Ascentage’s Co-founder and CSO, and the Warner-Lambert/Parke-Davis Professor in Medicine at the University of Michigan, among other internationally recognized clinical oncology researchers and specialists.